Abstract
SARS-CoV-2 enters host cells after binding through its spike glycoprotein to the angiotensin-converting enzyme 2 (ACE2) receptor. Soluble ACE2 ectodomains bind and neutralize the virus, yet their short in vivo half-live limits their therapeutic use. This limitation can be overcome by fusing the fragment crystallizable (Fc) part of human immunoglobulin G (IgG) to the ACE2 ectodomain, but this bears the risk of Fc-receptor activation and antibody-dependent cellular cytotoxicity. Here, we describe optimized ACE2-IgG4-Fc fusion constructs that avoid Fc-receptor activation, preserve the desired ACE2 enzymatic activity and show promising pharmaceutical properties. The engineered ACE2-IgG4-Fc fusion proteins neutralize the original SARS-CoV, pandemic SARS-CoV-2 as well as the rapidly spreading SARS-CoV-2 alpha, beta and delta variants of concern. Importantly, these variants of concern are inhibited at picomolar concentrations proving that ACE2-IgG4 maintains – in contrast to therapeutic antibodies – its full antiviral potential. Thus, ACE2-IgG4-Fc fusion proteins are promising candidate anti-antivirals to combat the current and future pandemics.
Keywords: Antiviral drug; Antiviral therapy; COVID-19; Entry inhibitor; Receptor trap.
【저자키워드】 COVID-19, antiviral therapy, antiviral drug, Entry inhibitor, Receptor trap., 【초록키워드】 SARS-CoV-2, IgG, antiviral therapy, ACE2, pandemic, Antiviral, antibody, SARS-CoV, spike glycoprotein, variants of concern, risk, delta variant, virus, angiotensin-converting enzyme 2, variants, antiviral drug, Immunoglobulin G, Immunoglobulin, therapeutic, Pandemics, Alpha, Beta, receptor, fusion protein, in vivo, antibody-dependent cellular cytotoxicity, binding, Angiotensin-converting enzyme, Concentration, angiotensin, therapeutic antibodies, IgG4, host cells, host cell, Activation, human immunoglobulin G, enzymatic activity, therapeutic use, ectodomain, TRAP, human immunoglobulin, limit, neutralize, inhibited, overcome, maintain, fusing, 【제목키워드】 SARS-CoV-2 variant, fusion protein,